How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
Identifieur interne : 002101 ( Main/Exploration ); précédent : 002100; suivant : 002102How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
Auteurs : E. Tanaka [Japon] ; N. Kurata [Japon] ; H. Yasuhara [Japon]Source :
- Journal of Clinical Pharmacy and Therapeutics [ 0269-4727 ] ; 2003-06.
English descriptors
- Teeft :
- Adverse effects, Blackwell publishing, British journal, Caffeine, Chlorzoxazone, Clinical pharmacology, Clinical pharmacy, Cocktail approach, Cortisol, Cyp3a, Cytochrome, Dapsone, Debrisoquine, Dextromethorphan, Drug metabolism, Enzyme phenotyping, Hepatic, Hplc, Hplc hplc, Human cytochrome, Hydroxylation, Mephenytoin, Metabolism, Metabolizing, Midazolam, Multiple probe drugs, Omeprazole, Other hand, Pharmacogenetics, Pharmacology, Phenotype, Phenotyping, Phenotyping method, Phenotyping probes, Plasma ratio, Plasma samples, Probe, Probe drug, Probe drugs, Selective phenotyping method, Simultaneous administration, Sparteine, Tanaka, Therapeutics, Tolbutamide, Urine, Urine metabolite ratio, Urine samples, Vivo, Vivo studies, Xanthine oxidase.
Abstract
Relatively selective in vivo substrate probes have been developed for several major CYP isoforms involved in oxidative drug metabolism. There are basically two in vivo methods for identifying the phenotype. One method, the selective (CYP‐specific) phenotyping method, involves administering one single probe drug, whereas the other is a mixed phenotyping or ‘cocktail’ method involving the simultaneous administration of multiple probe drugs, specific for the individual P450. At present, caffeine and chlorzoxazone are used most often as probe drugs for CYP1A2 and CYP2E1, respectively, but these are not necessarily the best probe drugs. Of the potential probe drugs for CYP2C9, CYP2C19, CYP2D6 and CYP3A4, none is really useful. Despite current limitations, the cocktail method for obtaining information about multiple CYP activities in a single experimental session is likely to be more widely used as a screening or phenotyping method for humans in the future.
Url:
DOI: 10.1046/j.1365-2710.2003.00486.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002387
- to stream Istex, to step Curation: 002387
- to stream Istex, to step Checkpoint: 000F37
- to stream Main, to step Merge: 002120
- to stream Main, to step Curation: 002101
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?</title><author><name sortKey="Tanaka, E" sort="Tanaka, E" uniqKey="Tanaka E" first="E." last="Tanaka">E. Tanaka</name></author><author><name sortKey="Kurata, N" sort="Kurata, N" uniqKey="Kurata N" first="N." last="Kurata">N. Kurata</name></author><author><name sortKey="Yasuhara, H" sort="Yasuhara, H" uniqKey="Yasuhara H" first="H." last="Yasuhara">H. Yasuhara</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:57DB5EBEAF56F5D9895376010054E89897264292</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1046/j.1365-2710.2003.00486.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-LXBFBDF7-9/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002387</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002387</idno><idno type="wicri:Area/Istex/Curation">002387</idno><idno type="wicri:Area/Istex/Checkpoint">000F37</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F37</idno><idno type="wicri:doubleKey">0269-4727:2003:Tanaka E:how:useful:is</idno><idno type="wicri:Area/Main/Merge">002120</idno><idno type="wicri:Area/Main/Curation">002101</idno><idno type="wicri:Area/Main/Exploration">002101</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?</title><author><name sortKey="Tanaka, E" sort="Tanaka, E" uniqKey="Tanaka E" first="E." last="Tanaka">E. Tanaka</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Institute of Community Medicine, University of Tsukuba, Ibaraki‐ken</wicri:regionArea><wicri:noRegion>Ibaraki‐ken</wicri:noRegion></affiliation></author><author><name sortKey="Kurata, N" sort="Kurata, N" uniqKey="Kurata N" first="N." last="Kurata">N. Kurata</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>School of Medicine, Showa University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Yasuhara, H" sort="Yasuhara, H" uniqKey="Yasuhara H" first="H." last="Yasuhara">H. Yasuhara</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>School of Medicine, Showa University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Clinical Pharmacy and Therapeutics</title><title level="j" type="alt">JOURNAL OF CLINICAL PHARMACY THERAPEUTICS</title><idno type="ISSN">0269-4727</idno><idno type="eISSN">1365-2710</idno><imprint><biblScope unit="vol">28</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="157">157</biblScope><biblScope unit="page" to="165">165</biblScope><biblScope unit="page-count">9</biblScope><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2003-06">2003-06</date></imprint><idno type="ISSN">0269-4727</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0269-4727</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adverse effects</term><term>Blackwell publishing</term><term>British journal</term><term>Caffeine</term><term>Chlorzoxazone</term><term>Clinical pharmacology</term><term>Clinical pharmacy</term><term>Cocktail approach</term><term>Cortisol</term><term>Cyp3a</term><term>Cytochrome</term><term>Dapsone</term><term>Debrisoquine</term><term>Dextromethorphan</term><term>Drug metabolism</term><term>Enzyme phenotyping</term><term>Hepatic</term><term>Hplc</term><term>Hplc hplc</term><term>Human cytochrome</term><term>Hydroxylation</term><term>Mephenytoin</term><term>Metabolism</term><term>Metabolizing</term><term>Midazolam</term><term>Multiple probe drugs</term><term>Omeprazole</term><term>Other hand</term><term>Pharmacogenetics</term><term>Pharmacology</term><term>Phenotype</term><term>Phenotyping</term><term>Phenotyping method</term><term>Phenotyping probes</term><term>Plasma ratio</term><term>Plasma samples</term><term>Probe</term><term>Probe drug</term><term>Probe drugs</term><term>Selective phenotyping method</term><term>Simultaneous administration</term><term>Sparteine</term><term>Tanaka</term><term>Therapeutics</term><term>Tolbutamide</term><term>Urine</term><term>Urine metabolite ratio</term><term>Urine samples</term><term>Vivo</term><term>Vivo studies</term><term>Xanthine oxidase</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Relatively selective in vivo substrate probes have been developed for several major CYP isoforms involved in oxidative drug metabolism. There are basically two in vivo methods for identifying the phenotype. One method, the selective (CYP‐specific) phenotyping method, involves administering one single probe drug, whereas the other is a mixed phenotyping or ‘cocktail’ method involving the simultaneous administration of multiple probe drugs, specific for the individual P450. At present, caffeine and chlorzoxazone are used most often as probe drugs for CYP1A2 and CYP2E1, respectively, but these are not necessarily the best probe drugs. Of the potential probe drugs for CYP2C9, CYP2C19, CYP2D6 and CYP3A4, none is really useful. Despite current limitations, the cocktail method for obtaining information about multiple CYP activities in a single experimental session is likely to be more widely used as a screening or phenotyping method for humans in the future.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement></list><tree><country name="Japon"><noRegion><name sortKey="Tanaka, E" sort="Tanaka, E" uniqKey="Tanaka E" first="E." last="Tanaka">E. Tanaka</name></noRegion><name sortKey="Kurata, N" sort="Kurata, N" uniqKey="Kurata N" first="N." last="Kurata">N. Kurata</name><name sortKey="Yasuhara, H" sort="Yasuhara, H" uniqKey="Yasuhara H" first="H." last="Yasuhara">H. Yasuhara</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002101 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002101 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:57DB5EBEAF56F5D9895376010054E89897264292
|texte= How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
}}
| This area was generated with Dilib version V0.6.33. |  |